Z-Ala-Ala-Asp-CMK

Z-Ala-Ala-Asp-CMK (Z-AAD-CMK) is a selective granzyme B inhibitor. By binding to the active site of granzyme B, Z-Ala-Ala-Asp-CMK blocks its proteolytic function. Z-Ala-Ala-Asp-CMK has anti-inflammatory activity and can be used in the research of inflammatory diseases and cancer[1][2].

Product Specifications

CAS Number

[183284-21-1]

Product Name Alternative

Z-AAD-CMK

UNSPSC

12352209

Target

Apoptosis; Caspase; Interleukin Related; Reactive Oxygen Species (ROS)

Type

Peptides

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/z-ala-ala-asp-cmk.html

Purity

98.14

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCC1=CC=CC=C1)N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(CCl)=O)=O)=O

Molecular Formula

C19H24ClN3O7

Molecular Weight

441.86

References & Citations

[1]Youichi Omoto, et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci. 2010 Aug;59 (2) :129-35.|[2]Yamamoto T, et al. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer. 2000 Oct;36 (15) :2007-17.